{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:40:57Z","timestamp":1790419257707,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T00:00:00Z","timestamp":1605052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2017R1A6A3A03003075"],"award-info":[{"award-number":["2017R1A6A3A03003075"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01AR075585"],"award-info":[{"award-number":["R01AR075585"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["NF150055"],"award-info":[{"award-number":["NF150055"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000861","name":"Burroughs Wellcome Fund","doi-asserted-by":"publisher","award":["DP5OD021351"],"award-info":[{"award-number":["DP5OD021351"]}],"id":[{"id":"10.13039\/100000861","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neurofibromatosis type I (NF1) is characterized by prominent skeletal manifestations caused by <jats:italic>NF1<\/jats:italic> loss. While inhibitors of the ERK activating kinases\u00a0MEK1\/2 are promising as a means to treat NF1, the broad blockade of the ERK pathway produced by this strategy is potentially associated with therapy limiting toxicities. Here, we have sought targets offering a more narrow inhibition of ERK activation downstream of NF1 loss in the skeleton, finding that MEKK2 is a novel component of a noncanonical ERK pathway in osteoblasts that mediates aberrant ERK activation after NF1 loss. Accordingly, despite mice with conditional deletion of <jats:italic>Nf1<\/jats:italic> in mature osteoblasts (<jats:italic>Nf1<\/jats:italic><jats:sup><jats:italic>fl\/fl<\/jats:italic><\/jats:sup><jats:italic>;Dmp1-Cre<\/jats:italic>) and <jats:italic>Mekk2<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup> each displaying skeletal defects, <jats:italic>Nf1<\/jats:italic><jats:sup><jats:italic>fl\/fl<\/jats:italic><\/jats:sup><jats:italic>;Mekk2<\/jats:italic><jats:sup><jats:italic>\u2212\/\u2212<\/jats:italic><\/jats:sup><jats:italic>;Dmp1-Cre<\/jats:italic> mice show an amelioration of NF1-associated phenotypes. We also provide proof-of-principle that FDA-approved inhibitors with activity against MEKK2 can ameliorate NF1 skeletal pathology. Thus, MEKK2 functions as a MAP3K in the ERK pathway in osteoblasts, offering a potential new therapeutic strategy for the treatment of NF1.<\/jats:p>","DOI":"10.1038\/s41467-020-19555-6","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T11:03:08Z","timestamp":1605092588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["MEKK2 mediates aberrant ERK activation in neurofibromatosis type I"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6063-1224","authenticated-orcid":false,"given":"Seoyeon","family":"Bok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Yeon","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisha R.","family":"Yallowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Eiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-4266","authenticated-orcid":false,"given":"Michelle","family":"Cung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9099-1829","authenticated-orcid":false,"given":"Jun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-762X","authenticated-orcid":false,"given":"Alfred L.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5987-9334","authenticated-orcid":false,"given":"John E.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4947-3293","authenticated-orcid":false,"given":"Jae-Hyuck","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-8532","authenticated-orcid":false,"given":"Matthew B.","family":"Greenblatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"19555_CR1","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0092-8674(01)00245-8","volume":"104","author":"K Cichowski","year":"2001","unstructured":"Cichowski, K. & Jacks, T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104, 593\u2013604 (2001).","journal-title":"Cell"},{"key":"19555_CR2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jbmr.2316","volume":"30","author":"J De La Croix Ndong","year":"2015","unstructured":"De La Croix Ndong, J. et al. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx\u2212\/\u2212 mice. J. Bone Miner. Res. 30, 55\u201363 (2015).","journal-title":"J. Bone Miner. Res."},{"key":"19555_CR3","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1172\/JCI63193","volume":"123","author":"T Chang","year":"2013","unstructured":"Chang, T. et al. Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice. J. Clin. Invest. 123, 335\u2013339 (2013).","journal-title":"J. Clin. Invest."},{"key":"19555_CR4","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1172\/JCI66167","volume":"123","author":"K Staser","year":"2013","unstructured":"Staser, K. et al. Normal hematopoiesis and neurofibromin- deficient myeloproliferative disease require Erk. J. Clin. Invest. 123, 329\u2013334 (2013).","journal-title":"J. Clin. Invest."},{"key":"19555_CR5","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","volume":"375","author":"E Dombi","year":"2016","unstructured":"Dombi, E. et al. Activity of selumetinib in neurofibromatosis type 1\u2013related plexiform neurofibromas. N. Engl. J. Med. 375, 2550\u20132560 (2016).","journal-title":"N. Engl. J. Med."},{"key":"19555_CR6","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/S0140-6736(07)61865-0","volume":"370","author":"TF Chu","year":"2007","unstructured":"Chu, T. F. et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370, 2011\u20132019 (2007).","journal-title":"Lancet"},{"key":"19555_CR7","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkel\u00e4","year":"2006","unstructured":"Kerkel\u00e4, R. et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 12, 908\u2013916 (2006).","journal-title":"Nat. Med."},{"key":"19555_CR8","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/nrc2106","volume":"7","author":"T Force","year":"2007","unstructured":"Force, T., Krause, D. S. & Van Etten, R. A. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat. Rev. Cancer 7, 332\u2013344 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"19555_CR9","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.3390\/ijms20081803","volume":"20","author":"J-M Kim","year":"2019","unstructured":"Kim, J.-M. et al. The ERK MAPK pathway is essential for skeletal development and homeostasis. Int. J. Mol. Sci. 20, 1803 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"19555_CR10","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1083\/jcb.200610046","volume":"176","author":"C Ge","year":"2007","unstructured":"Ge, C., Xiao, G., Jiang, D. & Franceschi, R. T. Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. J. Cell Biol. 176, 709\u2013718 (2007).","journal-title":"J. Cell Biol."},{"key":"19555_CR11","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1128\/MCB.01549-08","volume":"29","author":"T Matsushita","year":"2009","unstructured":"Matsushita, T. et al. Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol. Cell. Biol. 29, 5843\u20135857 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"19555_CR12","doi-asserted-by":"crossref","first-page":"6438","DOI":"10.1074\/jbc.M113.536300","volume":"289","author":"H Matsui","year":"2014","unstructured":"Matsui, H. et al. The expression of Fn14 via mechanical stress-activated JNK contributes to apoptosis induction in osteoblasts. J. Biol. Chem. 289, 6438\u20136450 (2014).","journal-title":"J. Biol. Chem."},{"key":"19555_CR13","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1172\/JCI42285","volume":"6","author":"MB Greenblatt","year":"2010","unstructured":"Greenblatt, M. B. et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J. Clin. Invest. 6, 2457\u20132473 (2010).","journal-title":"J. Clin. Invest."},{"key":"19555_CR14","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.bbrc.2011.02.127","volume":"408","author":"N Fukuno","year":"2011","unstructured":"Fukuno, N. et al. TGF-\u03b2-activated kinase 1 mediates mechanical stress-induced IL-6 expression in osteoblasts. Biochem. Biophys. Res. Commun. 408, 202\u2013207 (2011).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"19555_CR15","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1172\/JCI59041","volume":"121","author":"W Zou","year":"2011","unstructured":"Zou, W. et al. MLK3 regulates bone development downstream of the faciogenital dysplasia protein FGD1 in mice. J. Clin. Invest. 121, 4383\u20134392 (2011).","journal-title":"J. Clin. Invest."},{"key":"19555_CR16","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1128\/MCB.00617-07","volume":"28","author":"S Provot","year":"2008","unstructured":"Provot, S. et al. A-Raf and B-Raf are dispensable for normal endochondral bone development, and parathyroid hormone-related peptide suppresses extracellular signal-regulated kinase activation in hypertrophic chondrocytes. Mol. Cell. Biol. 28, 344\u2013357 (2008).","journal-title":"Mol. Cell. Biol."},{"key":"19555_CR17","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1074\/jbc.271.10.5361","volume":"271","author":"JL Blank","year":"2002","unstructured":"Blank, J. L., Gerwins, P., Elliott, E. M., Sather, S. & Johnson, G. L. Molecular cloning of mitogen-activated protein\/ERK kinase kinases (MEKK) 2 and 3. J. Biol. Chem. 271, 5361\u20135368 (2002).","journal-title":"J. Biol. Chem."},{"key":"19555_CR18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1074-7613(00)80116-8","volume":"11","author":"BC Schaefer","year":"1999","unstructured":"Schaefer, B. C. et al. Live cell fluorescence imaging of T cell MEKK2: redistribution and activation in response to antigen stimulation of the T cell receptor. Immunity 11, 411\u2013421 (1999).","journal-title":"Immunity"},{"key":"19555_CR19","doi-asserted-by":"crossref","first-page":"14784","DOI":"10.1074\/jbc.M010134200","volume":"276","author":"B Su","year":"2001","unstructured":"Su, B., Cheng, J., Yang, J. & Guo, Z. MEKK2 is required for T-cell receptor signals in JNK activation and interleukin-2 gene expression. J. Biol. Chem. 276, 14784\u201314790 (2001).","journal-title":"J. Biol. Chem."},{"key":"19555_CR20","doi-asserted-by":"crossref","first-page":"14489","DOI":"10.1074\/jbc.272.22.14489","volume":"272","author":"K Deacon","year":"2002","unstructured":"Deacon, K. & Blank, J. L. Characterization of the mitogen-activated protein kinase kinase 4 (MKK4)\/c-Jun NH 2 -terminal kinase 1 and MKK3\/p38 pathways regulated by MEK kinases 2 and 3. J. Biol. Chem. 272, 14489\u201314496 (2002).","journal-title":"J. Biol. Chem."},{"key":"19555_CR21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.emboj.7600913","volume":"25","author":"D Zhang","year":"2006","unstructured":"Zhang, D. et al. Identification of MEKK2\/3 serine phosphorylation site targeted by the Toll-like receptor and stress pathways. EMBO J. 25, 97\u2013107 (2006).","journal-title":"EMBO J."},{"key":"19555_CR22","doi-asserted-by":"crossref","first-page":"E1226","DOI":"10.1073\/pnas.1600813113","volume":"113","author":"MB Greenblatt","year":"2016","unstructured":"Greenblatt, M. B. et al. MEKK2 mediates an alternative \u03b2-catenin pathway that promotes bone formation. Proc. Natl Acad. Sci. USA 113, E1226\u2013E1235 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"19555_CR23","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0092-8674(04)00344-7","volume":"117","author":"X Yang","year":"2004","unstructured":"Yang, X. et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell 117, 387\u2013398 (2004).","journal-title":"Cell"},{"key":"19555_CR24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2004.03.006","volume":"35","author":"I Kalajzic","year":"2004","unstructured":"Kalajzic, I. et al. Dentin matrix protein 1 expression during osteoblastic differentiation, generation of an osteocyte GFP-transgene. Bone 35, 74\u201382 (2004).","journal-title":"Bone"},{"key":"19555_CR25","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/jbmr.3155","volume":"32","author":"N Kamiya","year":"2017","unstructured":"Kamiya, N. et al. Targeted disruption of NF1 in osteocytes increases FGF23 and osteoid with osteomalacia-like bone phenotype. J. Bone Miner. Res. 32, 1716\u20131726 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"19555_CR26","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/hmg\/ddm032","volume":"16","author":"M Kolanczyk","year":"2007","unstructured":"Kolanczyk, M. et al. Multiple roles for neurofibromin in skeletal development and growth. Hum. Mol. Genet. 16, 874\u2013886 (2007).","journal-title":"Hum. Mol. Genet."},{"key":"19555_CR27","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1093\/hmg\/ddr310","volume":"20","author":"W Wang","year":"2011","unstructured":"Wang, W. et al. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Hum. Mol. Genet. 20, 3910\u20133924 (2011).","journal-title":"Hum. Mol. Genet."},{"key":"19555_CR28","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1373\/clinchem.2016.259085","volume":"63","author":"MB Greenblatt","year":"2017","unstructured":"Greenblatt, M. B., Tsai, J. N. & Wein, M. N. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin. Chem. 63, 464\u2013474 (2017).","journal-title":"Clin. Chem."},{"key":"19555_CR29","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.bbrc.2015.06.029","volume":"463","author":"S Ahmad","year":"2015","unstructured":"Ahmad, S., Johnson, G. L. & Scott, J. E. Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity. Biochem. Biophys. Res. Commun. 463, 888\u2013893 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"19555_CR30","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1087057112466430","volume":"18","author":"S Ahmad","year":"2013","unstructured":"Ahmad, S., Hughes, M. A., Johnson, G. L. & Scott, J. E. Development and validation of a high-throughput intrinsic ATPase activity assay for the discovery of MEKK2 inhibitors. J. Biomol. Screen. 18, 388\u2013399 (2013).","journal-title":"J. Biomol. Screen."},{"key":"19555_CR31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbrc.2018.01.027","volume":"496","author":"S Ahmad","year":"2018","unstructured":"Ahmad, S. et al. Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2). Biochem. Biophys. Res. Commun. 496, 205\u2013211 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"19555_CR32","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/nm.3583","volume":"20","author":"J De La Croix Ndong","year":"2014","unstructured":"De La Croix Ndong, J. et al. Asfotase-\u03b1 improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1. Nat. Med. 20, 904\u2013910 (2014).","journal-title":"Nat. Med."},{"key":"19555_CR33","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1093\/hmg\/ddt333","volume":"22","author":"R Sharma","year":"2013","unstructured":"Sharma, R. et al. Hyperactive Ras\/MAPK signaling is critical for tibial nonunion fracture in neurobromin-decient mice. Hum. Mol. Genet. 22, 4818\u20134828 (2013).","journal-title":"Hum. Mol. Genet."},{"key":"19555_CR34","doi-asserted-by":"publisher","unstructured":"O\u2019Hare, T. et al. AP24534, a Pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. https:\/\/doi.org\/10.1016\/j.ccr.2009.09.028 (2009).","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"19555_CR35","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1158\/1535-7163.MCT-10-1044","volume":"10","author":"JM Gozgit","year":"2011","unstructured":"Gozgit, J. M. et al. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol. Cancer Ther. 10, 1028\u20131035 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"19555_CR36","doi-asserted-by":"crossref","first-page":"eaau0731","DOI":"10.1126\/sciadv.aau0731","volume":"4","author":"JP Choi","year":"2018","unstructured":"Choi, J. P. et al. Ponatinib (AP24534) inhibits MEKK3-KLF signaling and prevents formation and progression of cerebral cavernous malformations. Sci. Adv. 4, eaau0731 (2018).","journal-title":"Sci. Adv."},{"key":"19555_CR37","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1634\/theoncologist.2015-0253","volume":"20","author":"JF Gainor","year":"2015","unstructured":"Gainor, J. F. & Chabner, B. A. Ponatinib: accelerated disapproval. Oncologist 20, 847\u2013848 (2015).","journal-title":"Oncologist"},{"key":"19555_CR38","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/1758834014566428","volume":"7","author":"SJ Welsh","year":"2015","unstructured":"Welsh, S. J. & Corrie, P. G. Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma. Ther. Adv. Med. Oncol. 7, 122\u2013136 (2015).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"19555_CR39","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1172\/JCI60578","volume":"123","author":"WJ Jessen","year":"2013","unstructured":"Jessen, W. J. et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin. Invest. 123, 340\u2013347 (2013).","journal-title":"J. Clin. Invest."},{"key":"19555_CR40","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1126\/science.276.5313.795","volume":"276","author":"HF Guo","year":"1997","unstructured":"Guo, H. F., The, I., Hannan, F., Bernards, A. & Zhong, Y. Requirement of Drosophila NF1 for activation of adenylyl cyclase by PACAP38-like neuropeptides. Science 276, 795\u2013798 (1997).","journal-title":"Science"},{"key":"19555_CR41","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1126\/science.276.5313.791","volume":"276","author":"I The","year":"1997","unstructured":"The, I. et al. Rescue of a Drosophila NF1 mutant phenotype by protein kinase A. Science 276, 791\u2013794 (1997).","journal-title":"Science"},{"key":"19555_CR42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bone.2017.02.012","volume":"98","author":"GS Baht","year":"2017","unstructured":"Baht, G. S., Nadesan, P., Silkstone, D. & Alman, B. A. Pharmacologically targeting beta-catenin for NF1 associated deficiencies in fracture repair. Bone 98, 31\u201336 (2017).","journal-title":"Bone"},{"key":"19555_CR43","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1128\/MCB.22.16.5761-5768.2002","volume":"22","author":"Z Guo","year":"2002","unstructured":"Guo, Z. et al. Disruption of Mekk2 in mice reveals an unexpected role for MEKK2 in modulating T-cell receptor signal transduction. Mol. Cell. Biol. 22, 5761\u20135768 (2002).","journal-title":"Mol. Cell. Biol."},{"key":"19555_CR44","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/154405910708600404","volume":"86","author":"Y Lu","year":"2007","unstructured":"Lu, Y. et al. DMP1 -Targeted Cre expression in odontoblasts and osteocytes. J. Dent. Res. 86, 320\u2013325 (2007).","journal-title":"J. Dent. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19555-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19555-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19555-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T01:47:36Z","timestamp":1670291256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-19555-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["19555"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-19555-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"assertion":[{"value":"2 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5704"}}